FIG. 2.

Incidence rates of VTE per 10,000 person-years between ages 50 and 79 by oral hormone therapy use and genetic risk groups. Age- and GRSspecific VTE incidences were presented by (A) oral HT use status, (B) type of HT use, (C) duration of HT use, and (D) HT initiation. Each line represents different levels of GRS; the yellow line for the low GRS, the blue line for the intermediate GRS, and the red line for the high GRS. BMI, body mass index; GRS, genetic risk score; HT, hormone therapy; VTE, venous thromboembolism.

VTE, venous thromboembolism; HT, hormone therapy; PY, person-years; GRS, genetic risk score.